Compounds > tildipirosin
Page last updated: 2024-11-13

tildipirosin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

20,23-dipiperidinyl-mycaminosyl-tylonolide: a veterinary antibiotic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24860548
CHEMBL ID3039509
SCHEMBL ID20204354
MeSH IDM0578946

Synonyms (39)

Synonym
CHEMBL3039509
s795at66jb ,
tildipirosin
tildipirosin [usan:inn]
(4r,5s,6s,7r,9r,11e,13e,15r,16r-6-((3,6-dideoxy-3-(dimethylamino)-beta-d-glucopyranosyl)oxy)-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2-(piperidin-1-yl)ethyl)-15-((piperidin-1-yl)methyl)oxacyclohexadeca-11,13-diene-2,10-dione
328898-40-4
zuprevo
unii-s795at66jb
D10492
zuprevo [veterinary] (tn)
tildipirosin (usan/inn)
tildipirosin [ema epar veterinary]
tildipirosin [usan]
tildipirosin [inn]
zuprevo component tildipirosin
tylonolide, 20-deoxo-23-deoxy-5-o-(3,6-dideoxy-3-(dimethylamino)-.beta.-d- glucopyranosyl)-20,23-di-1-piperidinyl-
tildipirosin component of zuprevo
tildipirosin [mi]
tildipirosin [green book]
S6423
HY-A0071
CS-3296
AC-32492
(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4s,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2-piperidin-1-ylethyl)-15-(piperidin-1-ylmethyl)-1-oxacyclohexadeca-11,13-diene-2,10-dione
AKOS027338675
mfcd13194925
J-018917
SCHEMBL20204354
DB11470
AS-35167
Q16069783
DTXSID70954546
tildipirosine
tildipirosina
tildipirosin (ema epar veterinary)
tildipirosinum
zuprevo (veterinary)
tylonolide, 20-deoxo-23-deoxy-5-o-(3,6-dideoxy-3-(dimethylamino)-beta-d-glucopyranosyl)-20,23-di-1-piperidinyl-
20,23-dipiperidinyl-mycaminosyl-tylonolide

Research Excerpts

Overview

Tildipirosin (TIP) is a novel 16-membered-ring macrolide authorized for the treatment of bovine and swine respiratory disease. It is a derivative of the naturally occurring compound tylosin.

ExcerptReferenceRelevance
"Tildipirosin (TIP) is a novel 16-membered-ring macrolide authorized for the treatment of bovine and swine respiratory disease. "( A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs.
Kilp, S; Menge, M; Nürnberger, M; Pridmore, A; Röpke, R; Rose, M; Shaw, A; Wilhelm, C, 2016)		2.11
"Tildipirosin is a derivative of the naturally occurring compound tylosin."( Visualizing the 16-membered ring macrolides tildipirosin and tilmicosin bound to their ribosomal site.
Andersen, NM; Douthwaite, S; Poehlsgaard, J; Warrass, R, 2012)		1.36
"Tildipirosin is a 16-membered-ring macrolide developed to treat bacterial pathogens, including Mannheimia haemolytica and Pasteurella multocida, that cause respiratory tract infections in cattle and swine. "( Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolides.
Andersen, NM; Douthwaite, S; Poehlsgaard, J; Warrass, R, 2012)		2.07

Treatment

ExcerptReferenceRelevance
"Tildipirosin-treated heifers had lower (P < 0.05) lung lesion scores when compared with DRX- and SAL-treated heifers."( Pulmonary lesions and clinical disease response to Mannheimia haemolytica challenge 10 days following administration of tildipirosin or tulathromycin.
Amrine, DE; Larson, RL; Mosier, DA; White, BJ, 2014)		1.33

Pharmacokinetics

ExcerptReferenceRelevance
" Mean residence time from the time of dosing to the time of last measurable concentration (MRT(last)) and terminal half-life (T(1/2) ) was 6 and 9 days, respectively."( Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Zschiesche, E, 2012)		0.7
" Mean residence time from the time of dosing to the time of last measurable concentration (MRTlast) and terminal half-life (T1/2) both were about 4 days."( Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Wilhelm, C; Zschiesche, E, 2013)		0.71

Bioavailability

ExcerptReferenceRelevance
" Absolute bioavailability was 78."( Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Zschiesche, E, 2012)		0.7

Dosage Studied

ExcerptRelevanceReference
" Mean residence time from the time of dosing to the time of last measurable concentration (MRT(last)) and terminal half-life (T(1/2) ) was 6 and 9 days, respectively."( Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Zschiesche, E, 2012)		0.7
" Mean residence time from the time of dosing to the time of last measurable concentration (MRTlast) and terminal half-life (T1/2) both were about 4 days."( Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Wilhelm, C; Zschiesche, E, 2013)		0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1873889Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^6 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873880Antibacterial activity against Staphylococcus aureus ATCC 25923 infected in kunming mouse assessed as reduction in viable pathogens at 32.5 mg/kg, iv measured after 1 hr2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873909Antibacterial activity against Klebsiella pneumoniae ATCC 13883 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873914Antibacterial activity against Pseudomonas aeruginosa LTP-3 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873891Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^4 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873895Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^4 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873911Antibacterial activity against Streptococcus dysgalactiae incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873916Ratio of MBC to MIC for Escherichia coli ATCC 259222022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873944Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in absence of foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873888Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^7 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873904Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in absence of foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873893Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^6 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873913Antibacterial activity against Escherichia coli incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873917Bactericidal activity against Staphylococcus aureus ATCC 29213 incubated for 20 to 24 hrs by CLSI based analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873912Antibacterial activity against Staphylococcus chromogenes incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873943Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 50% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873892Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^3 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873946Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 10% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873947Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 25% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873915Bactericidal activity against Escherichia coli ATCC 25922 incubated for 20 to 24 hrs by CLSI based analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873910Antibacterial activity against Enterococcus faecium incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873921Bactericidal activity against Escherichia coli ATCC 25922 assessed as reduction in number of viable bacteria at 4 times MIC measured after 6 hrs by time kill assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873896Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^5 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873894Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^7 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873885Inhibition of protein synthesis in Escherichia coli ATCC 25922 assessed as reduction in protein content at 4 mg/ml measured upto 12 hrs by microporous enzyme labeling method relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873886Inhibition of DNA synthesis in Escherichia coli ATCC 25922 at 4 mg/ml measured upto 12 hrs by DAPI staining based fluorescence microscopic analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873940Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 5% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873890Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^5 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873945Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 5% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873901Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 50% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873906Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873918Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873919Ratio of MBC to MIC for Staphylococcus aureus ATCC 292132022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873905Antibacterial activity against Staphylococcus aureus incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873897Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^3 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873942Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 25% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873941Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 10% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873908Antibacterial activity against Cronobacter sakazakii ATCC 29544 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873907Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (65.00)24.3611
2020's7 (35.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.31 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index57.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (45.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (55.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
meglumine
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.		8.711hexosamine;
secondary amino compound
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.4110glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
thiamphenicol
[no description available]		3.711monocarboxylic acid amide;
sulfone		antimicrobial agent;
immunosuppressive agent
clonixin
Clonixin: Anti-inflammatory analgesic.. clonixin : A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks.		3.711aminopyridine;
organochlorine compound;
pyridinemonocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
vasodilator agent
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.4110amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
flunixin meglumine
flunixin meglumine : An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs.		8.711organoammonium saltantipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
danofloxacin
[no description available]		7.4110quinolines
florfenicol
florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.		10.0532organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone		antimicrobial agent
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.4110alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
linezolid
[no description available]		2.4110acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
tylosin
[no description available]		2.4110aldehyde;
disaccharide derivative;
enone;
leucomycin;
macrolide antibiotic;
monosaccharide derivative		allergen;
bacterial metabolite;
environmental contaminant;
xenobiotic
mycaminosyltylonolide
mycaminosyltylonolide: structure given in first source. 5-O-mycaminosyltylonolide : A macrolide antibiotic that is tylonolide having a beta-D-mycaminosyl residue attached at position 5.		2.4110aldehyde;
enone;
macrolide antibiotic;
monosaccharide derivative
tulathromycin
tulathromycin: structure in first source		4.9642aminoglycoside
tilmicosin
tilmicosin: semi-synthetic antibiotic. tilmicosin : A macrolide antibiotic with formula C46H80N2O13. It is used for the treatment of respiratory disease in cattle at high risk of developing bovine respiratory disease associated with Mannheimia haemolytica.		7.4820
tylosin
[no description available]		7.49168
oxytetracycline, anhydrous
Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.		2.5920
gamithromycin
gamithromycin: an antibiotic used in cattle. gamithromycin : A macrolide antibiotic with formula C40H76N2O12. It is used for the treatment of of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle. The compound is also licensed in Europe for the treatment of footrot in sheep caused by Dichelobacter nodosus and Fusobacterium nodosus.		7.920macrolide antibiotic;
monosaccharide derivative		antibacterial drug;
protein synthesis inhibitor
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.610cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiac Toxicity
[description not available]		02.4110
Equine Diseases
[description not available]		02.4110
Innate Inflammatory Response
[description not available]		02.4110
Infections, Respiratory
[description not available]		02.4110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.4110
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.4110
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.		02.4110
Mastitis, Bovine
INFLAMMATION of the UDDER in cows.		02.4110
Bovine Diseases
[description not available]		05.8754
Middle Ear Inflammation
[description not available]		04.7722
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		05.0132
Otitis Media
Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.		09.7722
Pneumonia
Infection of the lung often accompanied by inflammation.		05.0132
Ear Infection
[description not available]		0421
Respiratory Tract Diseases
Diseases involving the RESPIRATORY SYSTEM.		03.5311
Bovine Respiratory Disease Complex
A multifactorial disease of CATTLE resulting from complex interactions between environmental factors, host factors, and pathogens. The environmental factors act as stressors adversely affecting the IMMUNE SYSTEM and other host defenses and enhancing transmission of infecting agents.		03.9521
Pasteurellosis, Pneumonic
Bovine respiratory disease found in animals that have been shipped or exposed to CATTLE recently transported. The major agent responsible for the disease is MANNHEIMIA HAEMOLYTICA and less commonly, PASTEURELLA MULTOCIDA or HAEMOPHILUS SOMNUS. All three agents are normal inhabitants of the bovine nasal pharyngeal mucosa but not the LUNG. They are considered opportunistic pathogens following STRESS, PHYSIOLOGICAL and/or a viral infection. The resulting bacterial fibrinous BRONCHOPNEUMONIA is often fatal.		03.4811
Brucella Infection
[description not available]		02.1110
Swine Diseases
Diseases of domestic swine and of the wild boar of the genus Sus.		02.1110
Brucellosis
Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.		02.1110
Bacterial Pneumonia
[description not available]		03.5111
Infections, Pasteurellaceae
[description not available]		03.5111
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.		03.5111
Weight Gain
Increase in BODY WEIGHT over existing weight.		03.5311